First announced in June 2021, the site will be WuXi STA’s second facility in the US, providing expanded capacity and greater flexibility to meet the needs of customers both in the US and worldwide.

The facility is expected to start operating in 2025 and will create roughly 500 full-time jobs by 2026. The first phase will provide formulation development, clinical and commercial drug product manufacturing services for a variety of oral and injectable dosage forms, as well as packaging, labeling, storage and distribution services for clinical trial materials and commercial drug products.

WuXi STA has 12 sites across the US, Europe and Asia that offer a range of services, as well as three other drug product manufacturing sites in Couvet, Switzerland, and Wuxi City and Shanghai in China.

Last month, the company opened a new continuous manufacturing plant for large-scale API and advanced intermediate production, as well as a large-scale oligonucleotide and peptide manufacturing facility at its Changzhou campus in China.

In addition, WuXi AppTec announced plans on Jul. 19 to invest up to $1.43 billion in a new R&D and manufacturing site in Singapore. The investment is expected to be made in stages over the next 10 years, depending on the company’s business needs.

Author: Elaine Burridge, Freelance Journalist